Key facts
- This page summarizes Robert Bindert Huizinga's Form 4 filing for Aurinia Pharmaceuticals Inc. (AUPH).
- 6 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 22 Sep 2021, 16:53.
Robert Bindert Huizinga - 21 Sep 2021 Form 4 Insider Report for Aurinia Pharmaceuticals Inc. (AUPH)
- Reporting relationship
- EVP of Research
- Issuer ticker
- AUPH
- Reported as of
- 21 Sep 2021
- Net transaction value
- -$701,818
- SEC form
- 4
- Accepted by SEC
- 22 Sep 2021, 16:53:34 UTC
- Prior SEC filing
- 14 Sep 2021
- Next SEC filing
- 26 Oct 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Robert Bindert Huizinga
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robert Bindert Huizinga filed Form 4 for Aurinia Pharmaceuticals Inc. (AUPH) on 22 Sep 2021.
Change
- Previous filing in this sequence was filed on 14 Sep 2021.
- Current net transaction value: -$701,818.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AUPH
transaction
Common Stock
Options Exercise
- Transaction value
- $42,080
- Shares
- +16,000
- Change %
- +15%
- Price
- $2.63
- Shares after
- 122,092
- Date
- 21 Sep 2021
- Ownership
- Direct
- Footnotes
- F1
AUPH
transaction
Common Stock
Options Exercise
- Transaction value
- $35,635
- Shares
- +11,136
- Change %
- +9.1%
- Price
- $3.20
- Shares after
- 133,228
- Date
- 21 Sep 2021
- Ownership
- Direct
- Footnotes
- F1
AUPH
transaction
Common Stock
Sale
- Transaction value
- $652,621
- Shares
- -27,136
- Change %
- -20%
- Price
- $24.05
- Shares after
- 106,092
- Date
- 21 Sep 2021
- Ownership
- Direct
- Footnotes
- F2, F3
AUPH
transaction
Common Stock
Sale
- Transaction value
- $126,912
- Shares
- -5,364
- Change %
- -5.1%
- Price
- $23.66
- Shares after
- 100,728
- Date
- 21 Sep 2021
- Ownership
- Direct
- Footnotes
- F2, F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AUPH
transaction
Derivative
Stock Option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -16,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 21 Sep 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 16,000
- Exercise price
- $2.63
- Footnotes
- F1, F5
AUPH
transaction
Derivative
Stock Option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -11,136
- Change %
- -10%
- Price
- $0.000000
- Shares after
- 98,864
- Date
- 21 Sep 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 11,136
- Exercise price
- $3.20
- Footnotes
- F1, F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 6 footnotes
Footnote F1
Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date.
Footnote F2
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
Footnote F3
The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $24.02 to $24.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Footnote F4
The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $23.64 to $23.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Footnote F5
The shares subject to the option are fully vested and immediately exercisable. They vested in three equal monthly installments from the grant date.
Footnote F6
The shares subject to the option are fully vested and immediately exercisable. They vested in thirty-six equal monthly installments from the grant date.